Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Endocrinol (Lausanne)
Main Authors: Grisanti, Salvatore, Cosentini, Deborah, Laganà, Marta, Morandi, Alessandra, Lazzari, Barbara, Ferrari, Laura, Volta, Alberto Dalla, Ambrosini, Roberta, Ferrari, Vittorio Domenico, Sigala, Sandra, Berruti, Alfredo
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Endocrinology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943871/
https://ncbi.nlm.nih.gov/pubmed/33716976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.624102
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki